Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?

Area of Science:

• Immunology
• Urology
• Pathology

Background:

• Chronic inflammation is increasingly recognized as a key factor in benign prostatic hyperplasia (BPH) progression.
• While inflammatory infiltrates are common in BPH, their specific triggers remain unclear, suggesting potential autoimmune involvement.

Purpose of the Study:

• To review the immunologic features of chronic inflammation in BPH.
• To interpret the role of these immune changes in BPH development and progression.

Main Methods:

• Histologic examination of BPH specimens.
• Analysis of immune cell infiltrates (CD4+ T lymphocytes) and cytokine profiles (IL-15, IFN-gamma, IL-2, TGF-beta, IL-4, IL-13, IL-17, IL-6, IL-8).
• Review of experimental prostatitis models and autoimmune components.

Main Results:

• BPH specimens exhibit predominantly CD4+ T lymphocyte infiltrates.
• Elevated levels of pro-inflammatory cytokines (IFN-gamma, IL-2, IL-17) and growth-related cytokines (IL-6, IL-8) are observed in BPH.
• A shift towards a T-helper 0/T-helper 2 cytokine pattern (IL-4, IL-13) occurs as BPH nodules mature.

Conclusions:

• Benign prostatic hyperplasia is fundamentally an immune inflammatory disease.
• Understanding immune dysregulation in BPH can guide the development of targeted therapies.